Study of Cetuximab in Combination With Tarceva in Patients With Solid Tumors

• Status: Completed
• Trial end date: 2007-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to find a safe and effective dose of the combination of cetuximab (Erbitux) and Tarceva (erlotinib).

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Cetuximab; Erlotinib Hydrochloride

Criteria

Inclusion Criteria:

• Measurable disease

• Life expectancy of at least 3 months

• Must have at least one prior chemotherapy containing a platinum

Exclusion Criteria:

• Known or documented brain metastases

• Prior cetuximab therapy